CTXR - Citius Pharmaceuticals Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 0.54 USD StockBonds Safety Grade: C- Altman Z-Score (Bankruptcy Risk): -4.04 StockBond Score: 1.67 Company Description Citius Pharmaceuticals Inc operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products Its efforts are particularly directed towards antiinfective treatments supporting cancer care various prescription medications and pioneering mesenchymal stem cell therapies MinoWrap A novel liquifying gelbased wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures HaloLido A topical formulation that blends a corticosteroid with lidocaine intended to deliver both antiinflammatory and numbing relief to individuals suffering from hemorrhoids NoveCite A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome ARDS IONTAK An engineered fusion protein combining IL2 and diphtheria toxin purposed for the treatment of patients experiencing persistent or recurrent cutaneous Tcell lymphoma Citius Pharmaceuticals Inc was founded in 2007 and is headquartered in Cranford New Jersey